The COMT Genotyping Test is a specialized diagnostic procedure offered by DNA Labs UAE, designed to analyze the catechol-O-methyltransferase (COMT) gene. This gene plays a critical role in the metabolism of catecholamines, such as dopamine, epinephrine, and norepinephrine, which are crucial for various bodily functions including mood regulation, cognition, and stress response. By examining the COMT gene, this test can help in understanding an individual's genetic predisposition to certain mental health conditions, including depression, anxiety, and schizophrenia, as well as their response to certain medications.
The test involves collecting a DNA sample, usually through a simple and non-invasive method like a saliva swab or a blood sample. The sample is then analyzed to identify variations or mutations in the COMT gene that may affect the enzyme's activity level. Understanding these genetic variations can be particularly useful in personalized medicine, allowing healthcare providers to tailor treatment plans for mental health conditions more effectively.
At DNA Labs UAE, the COMT Genotyping Test is priced at 7200 AED. This cost reflects the comprehensive analysis and the personalized insights provided, which can be invaluable in managing and understanding an individual's mental health and wellbeing.
The Clopidogrel CYP2C19 Genotype Test is a specialized diagnostic procedure designed to assess how an individual's genetic makeup affects their response to clopidogrel, a medication commonly prescribed to prevent blood clots in patients with heart conditions or those who have undergone certain heart procedures. The effectiveness and metabolism of clopidogrel can vary significantly among individuals, primarily due to variations in the CYP2C19 gene. This test identifies specific genetic variants of the CYP2C19 enzyme that can influence the body's ability to process clopidogrel, thereby helping healthcare providers to tailor treatment plans more effectively and reduce the risk of adverse drug reactions.
Performed at DNA Labs UAE, a leading facility in genetic testing, the Clopidogrel CYP2C19 Genotype Test is priced at 8420 AED. The test involves a simple and non-invasive sample collection process, after which the sample is analyzed to detect the presence of genetic variations in the CYP2C19 gene. The results of this test can significantly impact patient care, guiding clinicians in deciding whether clopidogrel is the right medication for their patient or if an alternative treatment should be considered based on the patient's genetic profile. This personalized approach to medication management aims to improve treatment efficacy and patient safety.
The "HLA Pre-Transplant Workup Sensitized Recipient Panel 3 Test" is a crucial diagnostic procedure performed prior to organ transplantation, specifically designed to assess the compatibility between the donor and the recipient. This test is particularly important for recipients who are considered "sensitized," meaning they have developed antibodies that could potentially react against the donor organ, leading to transplant rejection or failure.
Performed at DNA Labs UAE, a leading facility in genetic and molecular diagnostics, this test involves a comprehensive analysis of the Human Leukocyte Antigen (HLA) system. HLA molecules play a critical role in the immune system's ability to distinguish between self and non-self, which is essential in the context of organ transplantation.
The test evaluates the recipient's immune response to potential donors, identifying the presence of specific antibodies that could target the donor HLA. This information is vital for the transplant team to select the most compatible donor, minimize the risk of organ rejection, and tailor immunosuppressive therapy more effectively.
The cost of the "HLA Pre-Transplant Workup Sensitized Recipient Panel 3 Test" at DNA Labs UAE is 8310 AED. This investment is essential for ensuring the best possible outcomes for patients undergoing organ transplantation, significantly contributing to the success rate and longevity of the transplanted organ.
The Oncomine Acute Myeloid Leukemia (AML) Panel Test is a sophisticated diagnostic tool offered by DNA Labs UAE, specifically designed to provide comprehensive genetic insights into acute myeloid leukemia, a type of cancer that affects the blood and bone marrow. This test utilizes next-generation sequencing technology to analyze multiple genes simultaneously, enabling the identification of genetic mutations and variations that may influence the development, progression, and treatment response of AML.
With a cost of 8260 AED, the Oncomine AML Panel Test is an investment in personalized medicine, offering patients and healthcare providers crucial information that can guide treatment decisions, predict therapeutic responses, and identify potential clinical trial opportunities. By pinpointing specific genetic abnormalities associated with AML, this test facilitates the selection of targeted therapies, potentially improving patient outcomes and reducing the likelihood of adverse reactions to treatment. Conducted at the state-of-the-art facilities of DNA Labs UAE, this test represents a significant step forward in the management and understanding of acute myeloid leukemia.
The Oncomine Chronic Myeloid Leukemia (CML) Panel Test is a comprehensive genomic profiling assay designed specifically for the analysis of genes associated with Chronic Myeloid Leukemia. This cutting-edge test, available at DNA Labs UAE, leverages next-generation sequencing (NGS) technology to identify key genetic mutations and variations in the DNA of patients diagnosed with CML. By analyzing a targeted panel of genes known to be implicated in the pathogenesis and progression of CML, the test provides critical insights that can guide personalized treatment strategies and decision-making.
With a cost of 8190 AED, the Oncomine CML Panel Test represents a significant investment in the precision medicine approach to cancer care. It enables healthcare providers to tailor treatments based on the specific genetic makeup of an individual’s cancer, potentially improving outcomes and minimizing unnecessary side effects. This test is particularly valuable for identifying resistance mutations that may affect the response to tyrosine kinase inhibitors, a common treatment for CML, thereby assisting clinicians in selecting the most effective therapy for their patients.
Performed at DNA Labs UAE, a facility renowned for its state-of-the-art genetic testing services, the Oncomine CML Panel Test is conducted under stringent quality controls to ensure accurate and reliable results. Patients undergoing this test can expect a thorough analysis of their condition, contributing to a more informed and personalized approach to their treatment plan.
The Oncomine Chronic Myelomonocytic Leukemia (CMML) Panel Test is a cutting-edge diagnostic tool designed to provide comprehensive genetic insights into chronic myelomonocytic leukemia, a rare type of cancer that affects the blood cells and bone marrow. This test is conducted at DNA Labs UAE, a leading facility in genetic and genomic testing. Priced at 8190 AED, the test utilizes next-generation sequencing technology to analyze specific gene mutations associated with CMML, enabling healthcare professionals to tailor treatment strategies to the individual patient's genetic profile. By identifying mutations in genes that are pivotal in the development and progression of CMML, the Oncomine CMML Panel Test aids in the diagnosis, prognosis, and monitoring of the disease, offering a personalized approach to patient care.
The Oncomine Juvenile Myelomonocytic Leukemia (JMML) Panel Test is a specialized diagnostic tool designed to provide comprehensive genomic insights into Juvenile Myelomonocytic Leukemia, a rare and aggressive form of leukemia typically affecting children under the age of four. Conducted at DNA Labs UAE, this test employs next-generation sequencing technology to analyze a specific set of genes known to be associated with JMML. By examining these genetic markers, the test aims to identify mutations and alterations that can influence treatment decisions and prognosis.
Priced at 8190 AED, the Oncomine JMML Panel Test is a valuable resource for healthcare professionals, offering a deeper understanding of the genetic underpinnings of the disease. This information is crucial for tailoring treatment strategies to the individual patient, potentially improving outcomes. The test is conducted in the state-of-the-art facilities of DNA Labs UAE, ensuring high-quality and reliable results.
The Oncomine Myelodysplastic Syndrome (MDS) Panel Test is a cutting-edge diagnostic tool designed to provide comprehensive genetic insights into myelodysplastic syndromes, a group of bone marrow disorders characterized by the bone marrow's inability to produce enough healthy blood cells. Conducted at DNA Labs UAE, this test utilizes next-generation sequencing technology to analyze multiple genes simultaneously, enabling the identification of specific genetic mutations associated with MDS. This information is crucial for the precise diagnosis, prognosis, and tailoring of treatment plans for individuals with MDS.
The test is priced at 8190 AED, reflecting the advanced technology and expertise required to perform this sophisticated analysis. By pinpointing specific genetic abnormalities, the Oncomine MDS Panel Test helps healthcare professionals make more informed decisions regarding patient care, potentially leading to improved treatment outcomes. DNA Labs UAE, known for its commitment to quality and accuracy, ensures that this test is conducted under stringent quality controls, providing reliable and timely results for patients and their families.
The Oncomine Myeloproliferative Neoplasm (MPN) Panel Test is a sophisticated genetic testing tool designed to aid in the diagnosis and management of myeloproliferative neoplasms. Conducted at DNA Labs UAE, this test utilizes next-generation sequencing technology to analyze multiple genes simultaneously, which are known to be associated with MPNs. These disorders are a group of blood cancers characterized by the overproduction of blood cells in the bone marrow, and they include conditions such as polycythemia vera, essential thrombocythemia, and myelofibrosis.
By examining specific genetic mutations, the Oncomine MPN Panel Test provides critical information that can help in determining the specific type of MPN, prognostic implications, and potential therapeutic options. This personalized approach to diagnosis and treatment planning is at the forefront of precision medicine, offering patients a tailored strategy to manage their condition effectively.
The test is priced at 8190 AED, reflecting the comprehensive analysis and the sophisticated technology involved. Conducted in the state-of-the-art facilities of DNA Labs UAE, patients can expect high standards of accuracy and reliability in their test results, contributing to better-informed decisions regarding their health care.
The "Oncopro Focus Fusion Panel for Solid Tumors Test" is an advanced diagnostic tool designed to provide comprehensive genetic insights into solid tumors. This test, conducted at DNA Labs UAE, is aimed at identifying specific gene fusions and alterations that are critical in the development, progression, and treatment response of various solid tumors. With a cost of 8190 AED, the test utilizes cutting-edge sequencing technologies to analyze a panel of genes associated with solid tumors, offering precise and personalized information that can guide targeted therapy decisions. By pinpointing the genetic underpinnings of a patient's tumor, the Oncopro Focus Fusion Panel enables healthcare providers to tailor treatment strategies more effectively, potentially improving patient outcomes. This test represents a significant step forward in the field of oncology, offering hope for more effective and individualized cancer care.
